T2-FLAIR不匹配征与较低级别弥漫性胶质瘤的11C-蛋氨酸摄取相关
研究纳入78例组织病理学证实的较低级别胶质瘤(2级31例,3级47例),分析T2-FLAIR不匹配征与11C-蛋氨酸PET摄取的关系。结果显示T2-FLAIR不匹配征见于16例(20.5%),其MET-PET中位T/N比值为1.50,显著低于无该征象者的1.83(p<0.001);在A组和W组中同样显著(1.50 vs 1.81,p=0.002)。结论认为T2-FLAIR不匹配征与较低级别胶质瘤中较低的11C-蛋氨酸摄取相关。
要点
- T2-FLAIR不匹配征在78例较低级别胶质瘤中见于16例(20.5%)。
- 有T2-FLAIR不匹配征者MET-PET中位T/N比值为1.50,低于无该征象者的1.83(p<0.001)。
- 在A组和W组中,有T2-FLAIR不匹配征者中位T/N比值为1.50,低于无该征象者的1.81(p=0.002)。
核心结论
- T2-FLAIR不匹配征与较低级别胶质瘤中较低的11C-蛋氨酸摄取相关。
研究设计与样本
- 纳入78例组织病理学证实的较低级别胶质瘤(2级31例,3级47例),所有患者组织学诊断前接受11C-蛋氨酸PET和MR成像。
- 由三名独立评估者评估MR图像上T2-FLAIR不匹配征的存在。
- 比较不同分子分型较低级别胶质瘤患者的分子状态、T2-FLAIR不匹配征和11C-蛋氨酸摄取。
主要发现
- 78例较低级别胶质瘤分为三组:A组(IDH突变且1p/19q非共缺失,n=22)、O组(IDH突变且1p/19q共缺失,n=20)、W组(IDH野生型,n=36)。
- T2-FLAIR不匹配征见于16例(20.5%),其中A组8例(36.4%)、O组0例(0%)、W组8例(22.2%)。
- 有T2-FLAIR不匹配征的肿瘤MET-PET中位T/N比值为1.50,显著低于无该征象者的1.83(p<0.001,Mann-Whitney U检验)。
- 在A组和W组(排除O组)中,有T2-FLAIR不匹配征的肿瘤中位T/N比值为1.50,显著低于无该征象者的1.81(p=0.002,Mann-Whitney U检验)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The T2-FLAIR mismatch sign is recognized as an imaging finding highly suggestive of IDH-mutant astrocytomas. This study was designed to determine whether the T2-FLAIR mismatch sign correlates with uptake of 11C-methionine in lower-grade gliomas. METHODS: We included 78 histopathologically verified lower-grade gliomas (grade 2: 31 cases, grade 3: 47 cases) in this study. 78 patients underwent 11C-methionine positron emission tomography (MET-PET) scans and magnetic resonance (MR) imaging scans prior to histological diagnosis. The tumor-to-normal ratio (T/N) of 11C-methionine uptake was calculated by dividing the maximum standardized uptake value (SUV) for the tumor by the mean SUV of the normal brain. MR imaging scans were evaluated for the presence of the T2-FLAIR mismatch sign by three independent reviewers. We compared molecular status, the T2-FLAIR mismatch sign and 11C-methionine uptake among patients with different lower-grade glioma molecular types. RESULTS: The 78 lower-grade gliomas were assigned to one of three molecular groups: Group A (IDH-mutant and 1p/19q non-codeleted, n = 22), Group O (IDH-mutant and 1p/19q codeleted, n = 20), and Group W (IDH wildtype, n = 36). T2-FLAIR mismatch was found in 16 cases (20.5%) that were comprised of 8 (36.4%), 0 (0%), 8 (22.2%) cases in the molecular group A, O and W, respectively. The median T/N ratio of MET-PET in tumors with T2-FLAIR mismatch was 1.50, which was significantly lower than that of tumors without T2-FLAIR mismatch (1.83, p < 0.001, Mann-Whitney U test). In the Groups A and W (excluding Group O), the median T/N ratio on MET-PET in groups A and W (but not group O) with T2-FLAIR mismatch was 1.50, which was significantly lower than that of tumors without T2-FLAIR mismatch (1.81, p = 0.002, Mann-Whitney U test). CONCLUSION: The T2-FLAIR mismatch sign correlated with lower 11C-methionine uptake in lower grade gliomas.
引用
- Ebiko Y, Tamura K, Hara S, et al. T2-FLAIR mismatch sign correlates with 11C-methionine uptake in lower-grade diffuse gliomas. J Neurooncol. 2023. PMID: 37589920. doi:10.1007/s11060-023-04417-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。